“Everyone was professional, pleasant, and competent. Dr. Schwartz was thorough, patient, and answered all questions about my first laser procedure. I appreciate them seeing me and protecting my vision.”
Giant Cell Arteritis and Eye Stroke: What You Need to Know
Who Is at Risk for Giant Cell Arteritis
Certain factors raise the likelihood of this diagnosis enough that your doctor uses them to decide how aggressively to pursue the workup. None of them alone decides anything, but together they shape the picture.
Giant cell arteritis typically affects people over the age of 50, and cases peak between ages 70 and 79, with an average age at onset around 75. At age 45, this diagnosis falls far down the list and attention shifts more heavily toward the heart and neck arteries. At age 74, it sits near the top of the list until blood tests provide further clarity.
Women develop giant cell arteritis roughly twice as often as men. The condition is more common in people of northern European and particularly Scandinavian ancestry, and it is less common in people of Asian and African American backgrounds. Being in a lower-risk group does not exclude you, and the blood tests and biopsy are what ultimately settle the question.
Polymyalgia rheumatica is a condition that causes stiffness and aching in the shoulders and hips, and it is present in a large portion of people diagnosed with giant cell arteritis. If you have ever been treated for polymyalgia rheumatica, let your care team know right away. This connection matters to the workup.
Giant cell arteritis is an immune reaction that occurs inside blood vessel walls. Screen time, reading habits, rubbing your eyes, and ordinary daily activities did not cause this condition. Knowing what is and is not responsible can help you focus on what actually matters for your care.
Symptoms of Giant Cell Arteritis
Many of the symptoms that point toward giant cell arteritis appear in the weeks before vision changes, not at the same moment. Looking back over recent weeks is as important as describing what happened the day your vision changed.
Headache occurs in roughly two thirds of people with giant cell arteritis, and jaw claudication (an aching in the jaw muscles that builds while you chew and fades when you stop) occurs in close to half. Scalp tenderness around the temples is also a recognized symptom. A practical way to recognize it: the arms of your glasses or a comb may suddenly feel painful to the touch, and a chewy meal causes an ache that builds as you eat.
Because this disease inflames arteries throughout the body, many people feel generally unwell for weeks before their vision is affected. Fever, fatigue, unexplained weight loss, and stiffness in the neck, hips, or arms are all recognized features. Body-wide symptoms occur in roughly half of patients. None of these signs mean much in isolation, but several of them appearing together after an eye stroke changes the direction of the workup significantly.
Many people experience a short episode where vision in one eye grays out for seconds to minutes and then returns. This is called transient visual loss, and it is a recognized warning sign. Among people who experienced this warning, a large proportion went on to permanent vision loss. If this happened to you before your main event, include it in your history even if you assumed it was nothing at the time. Double vision is also a recognized symptom of this condition.
Some patients have no headache, no jaw pain, and no general illness before their vision is affected. In these cases, which doctors call an occult presentation, the eye is the first and only sign. Testing is driven by your age and the appearance of your retina, not by whether your head hurts. Blood test results can also appear closer to normal than expected in patients with eye involvement, which means near-normal labs reduce suspicion but do not close the door on the diagnosis.
How Your Doctor Tests for Giant Cell Arteritis
The diagnostic workup moves quickly and involves both your eye examination and same-day blood tests. The goal is to either confirm or reasonably rule out arteritic disease before the window for protecting your second eye closes.
The erythrocyte sedimentation rate (a measure of how quickly red blood cells settle in a test tube) and C-reactive protein (a marker of inflammation) carry most of the early diagnostic weight. Both results can return within hours. The sedimentation rate is above 50 in most confirmed cases, and only a very small percentage of confirmed cases have both a normal sedimentation rate and a normal C-reactive protein. A complete blood count is also typically ordered. Normal results are reassuring but not conclusive, particularly when eye involvement is present.
A temporal artery biopsy removes a short segment of the artery at your temple under local anesthetic. The area remains safe because other vessels supply the same region. The specimen should be at least 1 centimeter long to improve accuracy. A positive biopsy result is close to conclusive. A negative result leaves some room for doubt, since the disease can skip along a vessel and the sampled segment may not capture affected tissue. In current United States practice, biopsy is the preferred confirmatory test over ultrasound.
Starting steroids before the biopsy is confirmed is not hasty. It is deliberate. The biopsy remains usable after treatment begins, and sensitivity is not meaningfully reduced within the first two weeks of therapy. The biopsy stays positive in a large proportion of cases even after months of steroid treatment. Nothing diagnostically important is lost by treating first, and the days saved are the days your second eye is still at risk.
Treatment for Giant Cell Arteritis
Treatment begins as soon as arteritic disease is suspected, and it continues for many months. The goals are to protect the eye you still see with, to prevent further vascular events, and to manage the significant demands that long-term steroid therapy places on your body.
Corticosteroids are the foundation of treatment, and speed matters more than the fine details of which form is used first. For newly diagnosed disease with threatened vision loss, current guidance conditionally favors pulse intravenous corticosteroids over high-dose oral steroids alone, though this is a preference rather than a settled superiority. The most important factor is that treatment begins the same day suspicion arises.
Tocilizumab, given by injection, is now part of standard care for many patients with this condition. Current guidance conditionally favors combining oral corticosteroids with tocilizumab rather than using corticosteroids alone. Clinical trial data showed that patients treated with weekly tocilizumab alongside a structured prednisone taper achieved sustained remission at one year at much higher rates than those on placebo, using roughly half the total steroid dose. Tocilizumab does not replace corticosteroids. It is added to them, and it reduces the overall steroid burden significantly.
This is important to understand clearly before treatment begins. Vision recovery in the eye already affected is uncommon. Treatment aims primarily at protecting the eye that still sees and at preventing further damage to blood vessels elsewhere in the body. That protection is a real and meaningful benefit, even when it is not the outcome patients first hope for. Discuss what success looks like with your Retina Specialist so you and your care team are measuring the same things.
Steroid therapy over many months carries real risks that require active monitoring. Recognized complications include weight gain, cataract formation (clouding of the eye lens), osteoporosis and fragility fractures, glucose intolerance or new-onset diabetes, high blood pressure, increased infection risk, and adrenal insufficiency. Calcium, vitamin D, and bone density monitoring are advised throughout treatment, along with regular blood glucose checks. Tocilizumab can reduce many of these risks by lowering the total steroid dose needed. If side effects become difficult to manage, discuss them with your care team rather than stopping treatment on your own.
Outlook, Risks, and What Recovery Looks Like
Understanding the realistic range of outcomes helps you and your care team make informed decisions at every step. Both the risks and the protections are meaningful, and knowing them gives you a clearer picture of what lies ahead.
Before corticosteroids were available, permanent vision loss affected close to half of all patients with this condition. Since treatment became standard, that rate has fallen considerably. This improvement is largely credited to faster diagnosis and earlier treatment, which is why speed consistently matters more than any fine point of drug selection.
Protecting the second eye is the central purpose of the entire treatment plan. In cases where the second eye follows the first, a large proportion of second events occur within one to seven days of the first. Getting onto treatment quickly narrows that window significantly. Data from studies using rapid-care pathways show that patients seen and treated quickly had lower rates of permanent vision loss than those who followed conventional, slower timelines.
An eye stroke is a blood vessel event, and the evaluation should reach beyond the eye itself. Research covering a large number of patients has shown a meaningfully elevated risk of brain stroke in the weeks following a retinal artery occlusion, with the highest risk concentrated in the first 30 days. This is why referral for a stroke evaluation is part of the recommended workup, regardless of whether giant cell arteritis is confirmed or not. In patients with confirmed giant cell arteritis affecting larger vessels, the long-term risk of aortic aneurysm (widening of the body's main artery) is also a recognized concern and is managed through your ongoing follow-up schedule.
When to Seek Care and Who Should Be on Your Team
Knowing which symptoms require same-day action and understanding how your care team is structured can make a real difference in outcomes. The emergency phase and the long-term monitoring phase require different responses, and being prepared for both matters.
Even after treatment begins, certain new symptoms should prompt an immediate call to your Retina Specialist rather than a wait-and-see approach. Contact your care team the same day if you notice any of the following.
- New blurring or vision loss in your second eye
- A dark curtain or shadow over part of your vision
- New double vision
- A sudden episode of vision going dark and then returning
- A new severe headache
- A sudden change in jaw or scalp pain
None of these necessarily mean treatment has failed. They mean your plan may need to be reviewed that day rather than at your next scheduled visit.
Once the acute emergency phase passes, care shifts to a long watch. The steroid taper typically runs 12 to 18 months, and roughly half of patients experience a relapse during or after that process. Visits continue well past the point where you feel recovered, because most relapses return as recognizable symptoms and are easier to manage when caught early. Long-term monitoring is the single strongest recommendation in current clinical guidance for this condition.
This condition crosses several specialties, and gaps between providers are where important details get missed. A Retina Specialist manages the eye and typically leads the initial diagnosis. A rheumatologist usually oversees the long-term taper and any tocilizumab therapy. Your primary care physician monitors bone health and blood sugar throughout treatment. Stroke evaluation should also be part of the plan. Ask which provider holds responsibility for each piece of your care and confirm you have a clear way to reach each of them.
Frequently Asked Questions
These answers address specific questions patients commonly have after going through an eye stroke workup, beyond what is covered in the sections above.
Normal results significantly reduce the likelihood, but they do not eliminate it. A very small percentage of confirmed cases have both a normal sedimentation rate and a normal C-reactive protein. Patients with eye involvement are more likely to have quieter lab results than those with other presentations. If your clinical picture still fits and your Retina Specialist has a high index of suspicion, treatment and biopsy may proceed even when lab values look reassuring.
Not with complete certainty. A biopsy samples one short segment of one artery, and this disease can affect arteries in patches, skipping areas in between. A positive result is nearly conclusive. A negative result reduces the probability but does not fully close the door, especially if your symptoms and blood markers remain consistent with the diagnosis. Some patients continue on treatment despite a negative biopsy based on the overall clinical picture.
In most cases, no, and it is better to know this clearly from the start. A small proportion of treated eyes show some recovery, but for the majority, the damage from the initial event is permanent. Treatment is aimed at protecting the eye that still has functional vision and at preventing further vascular events throughout the body. That goal is both real and important, even when it is different from what patients initially hope for.
Yes, and this is one of the most critical things to understand about this condition. A meaningful percentage of patients with biopsy-confirmed disease and eye involvement have no body-wide symptoms whatsoever. Doctors refer to this as an occult presentation. Your age and the appearance of your retina on examination drive the decision to test, not whether your head hurts. Waiting for a headache before pursuing the workup would result in missed diagnoses in a real subset of patients.
Because the biopsy determines how long you stay on a demanding treatment. A confirmed diagnosis supports a year or more of therapy with significant side effects and monitoring requirements. A workup that points away from the diagnosis may spare you that course. The good news is that the biopsy remains diagnostically reliable within the first two weeks of steroid therapy, and it continues to show positive results in a large proportion of confirmed cases even after months of treatment. The biopsy is not a formality. It shapes the entire plan going forward.
The same day, without waiting to see whether it settles on its own. In untreated patients who lose vision in a second eye, a large proportion of those second events occur within one to seven days of the first. If you can reach your Retina Specialist quickly, call them first. If not, go to an emergency room without delay. The window for protecting meaningful vision in that eye is narrow, and acting the same day is the most important thing you can do.
Expert Retinal Care on the Delmarva Peninsula
At Atlantic Retina Center, our team of fellowship-trained, ABO board-certified Retina Specialists is dedicated exclusively to conditions of the retina, vitreous, and macula, including the urgent evaluation and management of eye stroke and giant cell arteritis. We bring specialized diagnostic imaging, deep clinical experience, and a genuine commitment to protecting your vision to every appointment. If you have experienced sudden vision changes or have been told you may need a retinal evaluation, we are here to help you get the right answers quickly.